Just an example of a small company gaining Breakthrough designation is all, and yes they do have to do a small additional study before they get approval for Firdapse for LEMS. Why should it matter if it is adjunct therapy or first line therapy? Why wouldn't Oncosec qualify for Breakthrough status if the combo results are great?
News 
Market Data 
Discover 
AI
